Everest Medicines Unveils Encouraging Phase 1b/2a Clinical Trial Outcomes of BTK Inhibitor EVER001 at European Renal Congress Everest Medicines presented promising outcomes from its Phase 1b/2a trial of EVER001, a novel BTK inhibitor targeting primary membranous nephropathy, at the European Renal Congress.

Everest Medicines Unveils Encouraging Phase 1b/2a Clinical Trial Outcomes of BTK Inhibitor EVER001 at European Renal Congress #China #Shanghai #EVER001 #Everest_Medicines #primary_membranous_nephropathy

Everest Medicines Reveals Promising Outcomes from Phase 1b/2a Trial of EVER001 for Primary Membranous Nephropathy Everest Medicines presents encouraging results from a Phase 1b/2a clinical trial of EVER001, a BTK inhibitor targeting primary membranous nephropathy that shows promising effectiveness and safety.

Everest Medicines Reveals Promising Outcomes from Phase 1b/2a Trial of EVER001 for Primary Membranous Nephropathy #China #Shanghai #Clinical_Trial #EVER001 #Everest_Medicines

Exciting Progress for Everest Medicines with Phase 1b/2a Trial of EVER001 Showing Promising Results Everest Medicines reports positive preliminary results from the Phase 1b/2a trial of EVER001, a new BTK inhibitor aimed at treating primary membranous nephropathy, showing significant clinical remission rates among participants.

Exciting Progress for Everest Medicines with Phase 1b/2a Trial of EVER001 Showing Promising Results #EVER001 #BTK_Inhibitor #Everest_Medicines #